Hi mate - I'd appreciate your input. Some other chap raised this point, and I don't think it's been addressed, yet.
Comparing Anson's DFS from 8 September 2022, to today's PFS from AZL, Anson appears to be more attractive; AZL's post-tax IRR of 23.9% v Anson's post-tax IRR of 37%.
This difference in returns looks to be due to the additional cost from the conversion charge for LCE (chapter 11.3 of AZL's PFS).Playing Devil's advocate - why should investors pick AZL over Anson when the latter will (allegedly) give them a better return?
What advantages do you see AZL has (if any) over Anson? Or Vulcan for that matter (I think LKE is a dead duck). I can't think of other comparators right now.
The market must see something otherwise the SP would have tanked by now. I just can't see what that 'something' is.
Would be really interested in your thoughts (or other holders, if they have them), in this regard.
- Forums
- ASX - By Stock
- AZL
- Ann: Prairie Lithium PFS Confirms Extremely Low Operating Cost
Ann: Prairie Lithium PFS Confirms Extremely Low Operating Cost, page-82
-
- There are more pages in this discussion • 104 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AZL (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.0¢ |
Change
-0.001(4.76%) |
Mkt cap ! $89.47M |
Open | High | Low | Value | Volume |
2.1¢ | 2.2¢ | 2.0¢ | $155.3K | 7.284M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
16 | 2365384 | 2.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.1¢ | 585419 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 2365384 | 0.020 |
7 | 1573157 | 0.019 |
22 | 4650349 | 0.018 |
22 | 5088231 | 0.017 |
17 | 5556412 | 0.016 |
Price($) | Vol. | No. |
---|---|---|
0.021 | 585419 | 4 |
0.022 | 2573452 | 8 |
0.023 | 8244683 | 9 |
0.024 | 4405063 | 15 |
0.025 | 2338744 | 11 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
AZL (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online